Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-18T20:04:20.757Z Has data issue: false hasContentIssue false

34 - Genetic basis for primary ovarian insufficiency

from Section 5 - Pathology

Published online by Cambridge University Press:  05 October 2013

Luca Persani
Affiliation:
Department of Clinical Sciences and Community Health, University ofMilan and Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Stephanie Sherman
Affiliation:
Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA
Lawrence Nelson
Affiliation:
Intramural Research Program on Reproductive and Adult Endocrinology, Integrative Reproductive Medicine Group, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
Alan Trounson
Affiliation:
California Institute for Regenerative Medicine
Roger Gosden
Affiliation:
Center for Reproductive Medicine and Infertility, Cornell University, New York
Ursula Eichenlaub-Ritter
Affiliation:
Universität Bielefeld, Germany
Get access

Summary

Introduction

Approximately 1% of women under the age of 40 years and 0.1% under the age of 30 years experience “premature menopause” [1]. “Premature menopause” or “premature ovarian failure” (POF) has generally been defined as 4–6 months of amenorrhea in women under the age of 40 years associated with serum gonadotropin concentrations in the postmenopausal range and hypoestrogenism (hypergonadotropic hypogonadism). Depending on the age of onset, the disorder can manifest as failure to enter pubertal development and the associated primary amenorrhea (PA), or secondary amenorrhea (SA) after the onset of menarche and the associated pubertal development [2, 3]. Substantial published evidence has demonstrated that POF may have a long and variable clinical course with the possibility of spontaneous remission and even pregnancy many years after the diagnosis. Therefore, the term primary ovarian insufficiency (POI) is now generally accepted as a less stigmatizing term to young women. It is, as well, a more scientifically accurate definition, to describe more clearly a continuum of intermittent and unpredictable ovarian function [4, 5]. The continuum is divided into two categories of clinical states: (1) POI that is overt, meaning that menstrual cycles have become irregular, and (2) POI that is occult (oPOI), meaning that the menstrual cycles are still regular but other evidence supports a conclusion that ovarian function is impaired [5].

POI generates two orders of consequences, hypoestrogenism and infertility at an early age. Hypoestrogenism can nowadays be acceptably treated by hormone replacement therapy, generally given until the age of physiological menopause. In contrast, fertility cannot be recovered when follicle-stimulating hormone (FSH) is in the menopausal range and the diagnosis of overt POI is made. Also, fertility may well be compromised in the phase of the disease when the clinical manifestations are absent (oPOI). The relevance of this disorder is growing dramatically in recent years because women tend to postpone their conception due to economic reasons or working opportunities.

Type
Chapter
Information
Biology and Pathology of the Oocyte
Role in Fertility, Medicine and Nuclear Reprograming
, pp. 394 - 408
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Coulam, CB, Adamson, SC, Annegers, JF.Incidence of premature ovarian failure. Obstet Gynecol 1986; 67: 604–6.Google ScholarPubMed
Timmreck, LS, Reindollar, RH.Contemporary issues in primary amenorrhea. Obstet Gynecol Clin North Am 2003; 30: 287–302.CrossRefGoogle ScholarPubMed
Beck-Peccoz, P, Persani, L. Premature ovarian failure. Orphanet J Rare Dis 2006; 1: 9.CrossRefGoogle ScholarPubMed
Welt, CK.Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol 2008; 68: 499–509.CrossRefGoogle ScholarPubMed
Nelson, LM.Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360: 606–14.CrossRefGoogle ScholarPubMed
Goswami, D, Conway, GS.Premature ovarian failure. Hum Reprod Update 2005; 11: 391–410.CrossRefGoogle Scholar
Simpson, JL.Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann NY Acad Sci 1135: 146–54.CrossRef
Persani, L, Rossetti, R, Cacciatore, C. Genes involved in human ovarian failure. J Mol Endocrinol 2010; 45: 257–79.CrossRefGoogle ScholarPubMed
Cramer, DW, Xu, H, Harlow, BL.Family history as a predictor of early menopause. Fertil Steril 1995; 64: 740–5.CrossRefGoogle ScholarPubMed
Torgerson, DJ, Thomas, RE, Reid, DM.Mothers and daughters menopausal ages: is there a link? Eur J Obstet Gynecol Reprod Biol 1997; 74: 63–6.CrossRefGoogle Scholar
Murabito, JM, Yang, Q, Fox, C, Wilson, PW, Cupples, LA.Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 3427–30.CrossRefGoogle Scholar
Stolk, L, Perry, JR, Chasman, DI, et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet 2012; 44: 260–8.CrossRefGoogle ScholarPubMed
Vegetti, W, Grazia, Tibiletti M, Testa, G, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod 1998; 13: 1796–800.CrossRefGoogle Scholar
Toniolo, D.X-linked premature ovarian failure: a complex disease. Curr Opin Genet Dev 2006; 16: 293–300.CrossRefGoogle ScholarPubMed
Persani, L, Rossetti, R, Cacciatore, C, Bonomi, M.Primary ovarian insufficiency: X chromosome defects and autoimmunity. J Autoimmun 2009; 33: 35–41.CrossRefGoogle ScholarPubMed
Tibiletti, MG, Testa, G, Vegetti, W, et al. The idiopathic forms of premature menopause and early menopause show the same genetic pattern. Hum Reprod 1999; 14: 2731–4.CrossRefGoogle ScholarPubMed
Sybert, VP, McCauley, E.Turner's syndrome. N Engl J Med 2004; 351: 1227–38.CrossRefGoogle ScholarPubMed
Fechner, PY, Davenport, ML, Qualy, RL, et al. Toddler Turner Study Group. Differences in follicle-stimulating hormone secretion between 45,X monosomy Turner syndrome and 45,X/46,XX mosaicism are evident at an early age. J Clin Endocrinol Metab 2006; 91: 4896–902.CrossRefGoogle ScholarPubMed
Pasquino, AM, Passeri, F, Pucarelli, I, Segni, M, Municchi, G.Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. J Clin Endocrinol Metab 1997; 82: 1810–13.Google Scholar
Livadas, S, Xekouki, P, Kafiri, G, et al. Spontaneous pregnancy and birth of a normal female from a woman with Turner syndrome and elevated gonadotropins. Fertil Steril 2005; 83: 769–72.CrossRefGoogle ScholarPubMed
Ogata, T, Matsuo, N.Turner syndrome and female sex chromosome aberrations: deduction of the principal factors involved in the development of clinical features. Hum Genet 1995; 95: 607–29.CrossRefGoogle ScholarPubMed
Zinn, AR, Ross, JL.Turner syndrome and haploinsufficiency. Curr Opin GenetDev 1998; 8: 322–7.CrossRefGoogle ScholarPubMed
Rizzolio, F, Pramparo, T, Sala, C, et al. 2009 Epigenetic analysis of the critical region I for premature ovarian failure: demonstration of a highly heterochromatic domain on the long arm of the mammalian X chromosome. J Med Genet 1998; 46: 585–92.CrossRefGoogle Scholar
Schlessinger, D, Herrera, L, Crisponi, L, et al. Genes and translocations involved in POF. Am J Med Genet 2002; 111: 328–33.CrossRefGoogle ScholarPubMed
Neufeld, M, Maclaren, N, Blizzard, RM. Autoimmune polyglandular syndromes. Pediatr Ann 1980; 9: 43–53.CrossRefGoogle ScholarPubMed
Ahonen, P, Myllarniemi, S, Sipila, I, Perheentupa, J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829–36.CrossRefGoogle Scholar
Nagamine, K, Peterson, P, Scott, HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17(4): 393–8.CrossRefGoogle ScholarPubMed
Finnish-German APECED ConsortiumAn autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17(4): 399–403.CrossRefGoogle Scholar
Anderson, MS, Venanzi, ES, Klein, L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298(5597): 1395–401.CrossRefGoogle ScholarPubMed
Soderbergh, A, Myhre, AG, Ekwall, O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89(2): 557–62.CrossRefGoogle ScholarPubMed
Tong, ZB, Bondy, CA, Zhou, J, Nelson, LM. A human homologue of mouse Mater, a maternal effect gene essential for early embryonic development. Hum Reprod 2002; 17(4): 903–11.CrossRefGoogle ScholarPubMed
Alimohammadi, M, Bjorklund, P, Hallgren, A, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 2008; 358(10): 1018–28.CrossRefGoogle ScholarPubMed
Tong, ZB, Nelson, LM. A mouse gene encoding an oocyte antigen associated with autoimmune premature ovarian failure. Endocrinology 1999; 140(8): 3720–6.CrossRefGoogle ScholarPubMed
Tong, ZB, Gold, L, Pfeifer, KE, et al. Mater, a maternal effect gene required for early embryonic development in mice. Nat Genet 2000; 26(3): 267–8.CrossRefGoogle ScholarPubMed
Tong, ZB, Gold, L, De Pol, A et al. Developmental expression and subcellular localization of mouse MATER, an oocyte-specific protein essential for early development. Endocrinology 2004; 145(3): 1427–34.CrossRefGoogle ScholarPubMed
Kim, B, Kan, R, Anguish, L, Nelson, LM, Coonrod, SA. Potential role for MATER in cytoplasmic lattice formation in murine oocytes. PLoS One 2010; 5(9): e12587.CrossRefGoogle ScholarPubMed
Otsuka, N, Tong, ZB, Vanevski, K, et al. Autoimmune oophoritis with multiple molecular targets mitigated by transgenic expression of mater. Endocrinology 2011; 152(6): 2465–73.CrossRefGoogle ScholarPubMed
Jasti, S, Warren, BD, McGinnis, LK, et al. The autoimmune regulator prevents premature reproductive senescence in female mice. Biol Reprod 2012; 86(4): 110.
Bakalov, VK, Anasti, JN, Calis, KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2005; 84(4): 958–65.CrossRefGoogle ScholarPubMed
Reato, G, Morlin, L, Chen, S, et al. Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab 2011; 96(8): E1255–61.CrossRefGoogle ScholarPubMed
Falorni, A, Laureti, S, Candeloro, P, et al. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002; 78(2): 270–9.CrossRefGoogle ScholarPubMed
Novosad, JA, Kalantaridou, SN, Tong, ZB, Nelson, LM. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 2003; 3(1): 2.CrossRefGoogle Scholar
Betterle, C, Volpato, M, Rees, SB, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82(3): 932–8.Google ScholarPubMed
Crisponi, L, Deiana, M, Loi, A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27: 159–66.CrossRefGoogle ScholarPubMed
Schmidt, D, Ovitt, CE, Anlag, K, et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 2004; 131: 933–42.CrossRefGoogle ScholarPubMed
Uda, M, Ottolenghi, C, Crisponi, L, et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet 2004; 13: 1171–81.CrossRefGoogle ScholarPubMed
Beysen, D, De Paepe, A, De Baere, E.Mutation update: FOXL2 mutations and genomic rearrangements in BPES. Hum Mutat 2009; 30: 158–69.CrossRefGoogle Scholar
Nallathambi, J, Laissue, P, Batista, F, et al. Differential functional effects of novel mutations of the transcription factor FOXL2 in BPES patients. Hum Mutat 2008; 29: E123–31.CrossRefGoogle ScholarPubMed
Laissue, P, Lakhal, B, Benayoun, BA, et al. Functional evidence implicating FOXL2 in non syndromic premature ovarian failure and in the regulation of the transcription factor OSR2. J Med Genet 2009; 46: 455–7.CrossRefGoogle ScholarPubMed
Rubio-Gozalbo, ME, Gubbels, CS, Bakker, JA, et al. Gonadal function in male and female patients with classic galactosemia. Hum Reprod Update 2010; 16: 177–88.CrossRefGoogle ScholarPubMed
Calderon, FRO, Phansalkar, AR, Crockett, DK, Miller, M, Mao, R. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum Mutat 2007; 28: 939–43.CrossRefGoogle ScholarPubMed
Tyfield, L, Reichardt, J, Fridovich-Keil, J, et al. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat 1999; 13: 417–30.3.0.CO;2-0>CrossRefGoogle Scholar
Waggoner, DD, Buist, NR, Donnell, GN.Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 1990; 13: 802–18.CrossRefGoogle ScholarPubMed
Gubbels, CS, Land, JA, Rubio-Gozalbo, ME.Fertility and impact of pregnancies on the mother and child in classic galactosemia. Obstet Gynecol Surv 2008; 63: 334–43.CrossRefGoogle Scholar
Mantovani, G, Spada, A.Mutations in the Gs alpha gene causing hormone resistance. Best Pract Res Clin Endocrinol Metab 2006; 20: 501–13.CrossRefGoogle Scholar
Luoma, P, Melberg, A, Rinne, JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004; 364: 875–82.CrossRefGoogle ScholarPubMed
Pagnamenta, AT, Taanman, JW, Wilson, CJ, et al. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma. Hum Reprod 2006; 21: 2467–73.CrossRefGoogle ScholarPubMed
Schiffmann, R, Tedeschi, G, Kinkel, RP, et al. Leukodystrophy in patients with ovarian dysgenesis. Ann Neurol 1997; 41: 654–61.CrossRefGoogle ScholarPubMed
Boltshauser, E, Barth, PG, Troost, D, Martin, E, Stallmach, T.“Vanishing white matter” and ovarian dysgenesis in an infant with cerebro-oculo-facio-skeletal phenotype. Neuropediatrics 2002; 33: 57–62.CrossRefGoogle Scholar
Kastan, MB, Bartek, J.Cell-cycle checkpoints and cancer. Nature 2004; 432: 316–23.CrossRefGoogle ScholarPubMed
Demirhan, O, Türkmen, S, Schwabe, GC, et al. A homozygous BMPR1B mutation causes a new subtype of acromesomelic chondrodysplasia with genital anomalies. J Med Genet 2005; 42: 314–17.CrossRefGoogle ScholarPubMed
Persani, L, Rossetti, R, Cacciatore, C, Fabre, S. Genetic defects of ovarian TGF-β-like factors and premature ovarian failure. J Endocrinol Invest 2011; 34: 244–51.CrossRefGoogle ScholarPubMed
Sherman, SL, Taylor, K, Allen, EG. FMR1 premutation: a leading cause of inherited ovarian dysfunction. In: Arrieta, I, Penagarikano, O, Telez, M, eds. Fragile Sites: New Discoveries and Changing Perspectives. Hauppauge, NY: Nova Science Publishers, Inc. 2006; 290–320.Google Scholar
Welt, CK, Smith, PC, Taylor, AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 2004; 89(9): 4569–74.CrossRefGoogle ScholarPubMed
Rohr, J, Allen, EG, Charen, K, et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod 2008; 23(5): 1220–5.CrossRefGoogle ScholarPubMed
Allen, EG, Sullivan, AK, Marcus, M, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007; 22: 2142–52.CrossRefGoogle ScholarPubMed
Hunter, JE, Epstein, MP, Tinker, SW, Charen, KH, Sherman, SL. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol 2008; 32(6): 553–9.CrossRefGoogle ScholarPubMed
Tassone, F, Hagerman, RJ, Taylor, AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000; 66(1): 6–15.CrossRefGoogle ScholarPubMed
Bachner, D, Manca, A, Steinbach, P, et al. Enhanced expression of the murine FMR1 gene during germ cell proliferation suggests a special function in both the male and the female gonad. Hum Mol Genet 1993; 2(12): 2043–50.CrossRefGoogle ScholarPubMed
Rife, M, Nadal, A, Mila, M, Willemsen, R. Immunohistochemical FMRP studies in a full mutated female fetus. Am J Med Genet A 2004; 124(2): 129–32.CrossRefGoogle Scholar
Schuettler, J, Peng, Z, Zimmer, J, et al. Variable expression of the Fragile X Mental Retardation 1 (FMR1) gene in patients with premature ovarian failure syndrome is not dependent on number of (CGG)n triplets in exon 1. Hum Reprod 2011; 26(5): 1241–51.CrossRefGoogle Scholar
Themmen, APN, Huhtaniemi, IT.Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000; 21: 551–83.CrossRefGoogle ScholarPubMed
Latronico, AC, Anasti, J, Arnhold, IJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996; 334: 507–12.CrossRefGoogle ScholarPubMed
Shimasaki, S, Moore, RK, Otsuka, F, Erickson, GF.The bone morphogenetic protein system in mammalian reproduction. Endocr Rev 2004; 25: 72–101.CrossRefGoogle ScholarPubMed
Fabre, S, Pierre, A, Mulsant, P, et al. Regulation of ovulation rate in mammals: contribution of sheep genetic models. Reprod Biol Endocrinol 2006; 4: 20.CrossRefGoogle ScholarPubMed
Di Pasquale, E, Beck-Peccoz, P, Persani, L.Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004; 75: 106–11.CrossRefGoogle ScholarPubMed
Rossetti, R, Di Pasquale, E, Marozzi, A, et al. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat 2009; 30: 804–10.CrossRefGoogle Scholar
Matzuk, MM, Finegold, MJ, Su, JG, Hsueh, AJ, Bradley, A.Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992; 360: 313–19.CrossRefGoogle ScholarPubMed
Chand, AL, Harrison, CA, Shelling, AN.Inhibin and premature ovarian failure. Hum Reprod Update 2010; 16: 39–50.CrossRefGoogle ScholarPubMed
Corre, T, Schuettler, J, Bione, S, et al. Italian Network for the study of Ovarian Dysfunctions. A large-scale association study to assess the impact of known variants of the human INHA gene on premature ovarian failure. Hum Reprod 2009; 24: 2023–8.CrossRefGoogle Scholar
Mansouri, MR, Schuster, J, Badhai, J, et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet 2008; 17: 3776–83.CrossRefGoogle Scholar
Mandon-Pépin, B, Touraine, P, Kuttenn, F, et al. Genetic investigation of four meiotic genes in women with premature ovarian failure. Eur J Endocrinol 2008; 158: 107–15.CrossRefGoogle ScholarPubMed
Luo, X, Ikeda, Y, Parker, KL.A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994; 77: 481–90.CrossRefGoogle ScholarPubMed
Lourenço, D, Brauner, R, Lin, L, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 2009; 360: 1200–10.CrossRefGoogle ScholarPubMed
Castrillon, DH, Miao, L, Kollipara, R, Horner, JW, DePinho, RA.Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003; 301: 215–18.CrossRefGoogle ScholarPubMed
Liu, L, Rajareddy, S, Reddy, P, et al. Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a. Development 2007; 134: 199–209.CrossRefGoogle ScholarPubMed
Watkins, WJ, Umbers, AJ, Woad, KJ, et al. Mutational screening of FOXO3A and FOXO1A in women with premature ovarian failure. Fertil Steril 2006; 86: 1518–21.CrossRefGoogle ScholarPubMed
Vinci, G, Christin-Maitre, S, Pasquier, M, et al. FOXO3a variants in patients with premature ovarian failure. Clin Endocrinol 2008; 68: 495–7.Google ScholarPubMed
Qin, Y, Choi, Y, Zhao, H, et al. NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet 2007; 81: 576–81.CrossRefGoogle ScholarPubMed
Bouilly, J, Bachelot, A, Broutin, I, Touraine, P, Binart, N. Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort. Hum Mutat 2011; 32: 1108–13.CrossRefGoogle Scholar
Zhao, H, Chen, ZJ, Qin, Y, et al. Transcription factor FIGLA is mutated in patients with premature ovarian failure. Am J Hum Genet 2008; 82: 1342–8.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Genetic basis for primary ovarian insufficiency
    • By Luca Persani, Department of Clinical Sciences and Community Health, University ofMilan and Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy, Stephanie Sherman, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA, Lawrence Nelson, Intramural Research Program on Reproductive and Adult Endocrinology, Integrative Reproductive Medicine Group, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
  • Edited by Alan Trounson, Roger Gosden, Ursula Eichenlaub-Ritter, Universität Bielefeld, Germany
  • Book: Biology and Pathology of the Oocyte
  • Online publication: 05 October 2013
  • Chapter DOI: https://doi.org/10.1017/CBO9781139135030.035
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Genetic basis for primary ovarian insufficiency
    • By Luca Persani, Department of Clinical Sciences and Community Health, University ofMilan and Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy, Stephanie Sherman, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA, Lawrence Nelson, Intramural Research Program on Reproductive and Adult Endocrinology, Integrative Reproductive Medicine Group, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
  • Edited by Alan Trounson, Roger Gosden, Ursula Eichenlaub-Ritter, Universität Bielefeld, Germany
  • Book: Biology and Pathology of the Oocyte
  • Online publication: 05 October 2013
  • Chapter DOI: https://doi.org/10.1017/CBO9781139135030.035
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Genetic basis for primary ovarian insufficiency
    • By Luca Persani, Department of Clinical Sciences and Community Health, University ofMilan and Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy, Stephanie Sherman, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA, Lawrence Nelson, Intramural Research Program on Reproductive and Adult Endocrinology, Integrative Reproductive Medicine Group, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
  • Edited by Alan Trounson, Roger Gosden, Ursula Eichenlaub-Ritter, Universität Bielefeld, Germany
  • Book: Biology and Pathology of the Oocyte
  • Online publication: 05 October 2013
  • Chapter DOI: https://doi.org/10.1017/CBO9781139135030.035
Available formats
×